**INDICATIONS AND USAGE**

ZIANA Gel is a combination of a lincosamide antibiotic and a retinoid, containing clindamycin phosphate 1.2% and tretinoin 0.025% gel in 30 and 60 gram tubes. (3)

**DOSAGE FORMS AND STRENGTHS**

ZIANA Gel is not for oral, ophthalmic, or intravaginal use. (2)

**WARNINGS AND PRECAUTIONS**

**ADVERSE REACTIONS**

The chemical name for tretinoin is 3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoic acid. The molecular formula is C34H34O2. The molecular weight is 300.44.

**CLINICAL STUDIES EXPERIENCE**

**PATIENT COUNSELING INFORMATION**

The concentration of tretinoin in ZIANA Gel exceeds the concentrations of tretinoin used in all of the clinical trials for acne. Therefore, skin irritation, such as dryness, scaling, itching, burning, and stinging, is expected.

**CONTRAINDICATIONS**

1. ZIANA Gel is not for oral, ophthalmic, or intravaginal use.

2. Hypersensitivity to any component of ZIANA Gel is a contraindication to its use.

**DOSE AND ADMINISTRATION**

Topical gel: Clindamycin phosphate 1.2% and tretinoin 0.025% gel in 30 and 60 gram tubes. (3)

**INDICATIONS AND USAGE**

ZIANA Gel is a combination of a lincosamide antibiotic and a retinoid, containing clindamycin phosphate 1.2% and tretinoin 0.025% gel in 30 and 60 gram tubes. (3)

**DOSAGE FORMS AND STRENGTHS**

ZIANA Gel is not for oral, ophthalmic, or intravaginal use. (2)

**WARNINGS AND PRECAUTIONS**

**ADVERSE REACTIONS**

The chemical name for tretinoin is 3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraenoic acid. The molecular formula is C34H34O2. The molecular weight is 300.44.

**CLINICAL STUDIES EXPERIENCE**

**PATIENT COUNSELING INFORMATION**
14. CLINICAL STUDIES

The safety and efficacy of ZIANA Gel for treatment of acne vulgaris were assessed in three clinical trials: Study 1, a 12-week, randomized, double-blind, placebo-controlled study in patients 12 years of age and older; Study 2 and 3 and of clinical design, and compared ZIANA Gel to clindamycin in this gel vehicle, wash-in, in the vehicle gel, and of the skin. Patients with mild, moderate, or severe acne were enrolled in the studies. The co-primary efficacy variables were:

(1) Mean percent change from baseline at Week 12:
- Inflammatory lesion counts
- Non-inflammatory lesion counts
- Total lesion counts

(2) Percent of subjects who cleared or almost cleared at Week 12 as judged by an Evaluator’s Global Severity (GS) score

In Study 1, a total of 1353 patients were enrolled, and in Study 2, a total of 1238 patients were enrolled. The combined results are presented in Table 1.

Table 1: Efficacy Results at Week 12 in Studies 1 and 2

<table>
<thead>
<tr>
<th>Lesion Type</th>
<th>Inflammatory</th>
<th>N (%)</th>
<th>Non-Inflammatory</th>
<th>N (%)</th>
<th>Total Lesion</th>
<th>N (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>ZIANA Gel</td>
<td>41%</td>
<td>68%</td>
<td>36%</td>
<td>60%</td>
<td>34%</td>
<td>58%</td>
</tr>
<tr>
<td>Placebo</td>
<td>36%</td>
<td>64%</td>
<td>31%</td>
<td>69%</td>
<td>26%</td>
<td>41%</td>
</tr>
<tr>
<td>Change in GS</td>
<td>47%</td>
<td>53%</td>
<td>41%</td>
<td>59%</td>
<td>31%</td>
<td>38%</td>
</tr>
</tbody>
</table>

In Study 3, ZIANA Gel was compared to clindamycin in a total of 2010 patients with moderate or severe acne. As with Studies 1 and 2, the primary endpoints were mean percent reduction in lesion counts (inflammatory, non-inflammatory, and total) and the GS score. In Study 3, success on the GS score was defined by the percentage of subjects who had at least 2 grades of improvement in their EGS scores. The EGS scoring scale used in all of the clinical trials for ZIANA Gel is as follows:

<table>
<thead>
<tr>
<th>Lesion Type</th>
<th>Inflammatory</th>
<th>N (%)</th>
<th>Non-Inflammatory</th>
<th>N (%)</th>
<th>Total Lesion</th>
<th>N (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>ZIANA Gel</td>
<td>36%</td>
<td>64%</td>
<td>36%</td>
<td>64%</td>
<td>30%</td>
<td>51%</td>
</tr>
<tr>
<td>Clindamycin</td>
<td>39%</td>
<td>61%</td>
<td>30%</td>
<td>70%</td>
<td>29%</td>
<td>45%</td>
</tr>
<tr>
<td>Change in GS</td>
<td>48%</td>
<td>52%</td>
<td>42%</td>
<td>58%</td>
<td>32%</td>
<td>38%</td>
</tr>
</tbody>
</table>

In Study 3, the results are presented in Table 2.

Table 2: Efficacy Results at Week 12 in Study 3

<table>
<thead>
<tr>
<th>Lesion Type</th>
<th>Inflammatory</th>
<th>N (%)</th>
<th>Non-Inflammatory</th>
<th>N (%)</th>
<th>Total Lesion</th>
<th>N (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>ZIANA Gel</td>
<td>36%</td>
<td>64%</td>
<td>36%</td>
<td>64%</td>
<td>30%</td>
<td>51%</td>
</tr>
<tr>
<td>Clindamycin</td>
<td>39%</td>
<td>61%</td>
<td>30%</td>
<td>70%</td>
<td>29%</td>
<td>45%</td>
</tr>
<tr>
<td>Change in GS</td>
<td>48%</td>
<td>52%</td>
<td>42%</td>
<td>58%</td>
<td>32%</td>
<td>38%</td>
</tr>
</tbody>
</table>

15 HOW SUPPLIED/STORAGE AND HANDLING

ZIANA Gel (clindamycin phosphate 1.2% and tretinoin 0.025%) Gel is supplied as follows:
- 60 gram tube NDC 99207-300-60

ZIANA Gel is supplied as a light orange, opaque gel containing clindamycin phosphate and tretinoin. Use ZIANA Gel exactly as prescribed. It may take some time to see improvement of your acne with ZIANA Gel. Your doctor will tell you how long to use ZIANA Gel.

16 PATIENT COUNSELING INFORMATION

Advise the patient to read the FDA-approved patient labeling (Patient Information).

Tell your doctor:
- If you are pregnant or planning to become pregnant. It is not known if ZIANA Gel may harm your unborn baby.
- If you are breastfeeding. ZIANA Gel may pass through your milk and may harm your baby.
- About all the medicines and skin products you use.
- ZIANA Gel should not be used with any antifungal-containing products.
- Avoid medicated or abrasive soaps and cleansers, and cosmetics that have a strong drying effect such as deodorant or antiperspirant.

In the morning:
- Apply ZIANA Gel in the morning and dry the skin.
- Do not use too much ZIANA Gel. Too much ZIANA Gel may irritate your skin.
- Do not wash your face until it is dry for at least 3 to 4 hours. Reapplying an ointment or ointment may irritate your skin.
- Avoid excessive exposure to the sun, cold, and wind. Weather extremes can dry and burn the skin. Always use a sunscreen on ZIANA Gel treated skin, even on cloudy days. Use the protectors clothing such as sun protection, sunglasses, and hats.

How should ZIANA Gel be used:

Use ZIANA Gel exactly as prescribed. It may take some time to see improvement of your acne with ZIANA Gel. Your doctor will tell you how long to use ZIANA Gel.

At bedtime:
- Wash your face with a mild soap and warm water.
- Pat the skin dry.
- Do not give ZIANA Gel to other people, even if they have the same symptoms you have. It may harm them.

General information about ZIANA Gel

ZIANA Gel contains clindamycin phosphate (1.2%) and tretinoin (0.025%) Gel.

What is ZIANA Gel?

ZIANA Gel is a prescription medicine used to treat acne vulgaris. ZIANA Gel is used to treat acne in people, even if they have the same symptoms you have. It may harm them.

ZIANA Gel may cause skin irritation such as dryness, redness, peeling, burning, or stinging. Stop ZIANA Gel and call your doctor if your skin becomes very red, swollen, blistered, or inflamed.

How should I store ZIANA Gel?

Keep ZIANA Gel and all medicines out of reach of children. Keep ZIANA Gel away from heat and light. Store at 25°C (77°F); excursions permitted to 15° to 30°C (59° to 86°F) [see USP , glycerin USP , methylparaben NF , polysorbate 80 NF , propylparaben NF , purified water USP and sodium hydroxide USP ].

What are the ingredients in ZIANA Gel?

ZIANA Gel contains clindamycin phosphate (1.2%) and tretinoin (0.025%).

Active ingredients: clindamycin phosphate 1.2% and tretinoin 0.025%

Inactive ingredients: butylated hydroxyanisole, sodium hydroxide, clindamycin N=426 (16%)

Vehicle N=1002 (48%)

Clindamycin N=70 (14%)

Use ZIANA Gel only as prescribed. It may take some time to see improvement of your acne with ZIANA Gel. Your doctor will tell you how long to use ZIANA Gel.